Lilly(US:LLY) Ge Long Hui·2025-09-26 08:59Group 1 - The core point of the article is that Eli Lilly (LLY.US) has received FDA approval for a new drug named Inluriyo, aimed at adult patients with previously treated advanced breast cancer, which has shown a 38% reduction in the risk of cancer progression or death compared to standard treatment [1] - The approval is based on data from a late-stage clinical trial [1] - Eli Lilly's president in India expressed willingness to collaborate in the country, indicating potential for the experimental weight-loss drug in the Indian market [1] Group 2 - The stock price of Eli Lilly increased by 2% in pre-market trading, reaching $728.85 [1] - The closing price before the announcement was $714.59, reflecting a decrease of 3.67% [1] - The company's total market capitalization is approximately $676.33 billion, with a price-to-earnings ratio of 61.02 [1]